Similar articles

• Radical locoregional therapy for bladder cancer: underutilized, or unsuitable in many?

  Black PC. Black PC. Eur Urol. 2013 May;63(5):830-1. doi: 10.1016/j.eururo.2012.12.061. Epub 2013 Jan 9. Eur Urol. 2013. PMID: 23317935 No abstract available.
• Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

  Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Gray PJ, et al. Eur Urol. 2013 May;63(5):823-9. doi: 10.1016/j.eururo.2012.11.015. Epub 2012 Nov 19. Eur Urol. 2013. PMID: 23200811
• Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11.

  Goyal NK, Garg M, Goel A. Goyal NK, et al. Eur Urol. 2012 Aug;62(2):e41; author reply e42. doi: 10.1016/j.eururo.2012.04.054. Epub 2012 May 8. Eur Urol. 2012. PMID: 22579049 No abstract available.
• [Noninvasive and invasive bladder cancer: diagnostics and treatment].

  Goebell PJ, Vom Dorp F, Rödel C, Frohneberg D, Thüroff JW, Jocham D, Stief C, Roth S, Knüchel R, Schmidt KW, Kausch I, Zaak D, Wiesner C, Miller K, Sauer R, Rübben H. Goebell PJ, et al. Urologe A. 2006 Jul;45(7):873-84; quiz 885. doi: 10.1007/s00120-006-1065-z. Urologe A. 2006. PMID: 16791629 Review. German.
• Non-transitional cell bladder carcinomas.

  Manunta A, Vincendeau S, Kiriakou G, Lobel B, Guillé F. Manunta A, et al. BJU Int. 2005 Mar;95(4):497-502. doi: 10.1111/j.1464-410X.2005.05327.x. BJU Int. 2005. PMID: 15705067 Review. No abstract available.